Laboratory parameters such as transaminases and parameters of cholestasis (e.g., AST, ALT, AP, and GGT) were determined at the timepoint of study inclusion (before the start of add-on therapy with OCA) and at the 6-month follow-up examination. The gene discussed is DHCR7-DT; the disease is cholestasis.